Latest news with #SaiLifeSciences
&w=3840&q=100)
Business Standard
20-06-2025
- Business
- Business Standard
Nippon India MF, BlackRock, others buy 10% stake in Sai Life for ₹1,505 cr
Nippon India Mutual Fund, BlackRock, Societe Generale, Morgan Stanley and others on Friday collectively bought a 10 per cent stake in Sai Life Sciences from US-based asset manager TPG for Rs 1,505 crore through open market transactions. Besides, Axis Mutual Fund (MF), Aditya Birla Sun Life MF, Invesco MF, Norway's Government Pension Fund Global, German multinational Allianz's arm Pimco, Axis Max Life Insurance, HDFC MF, Ghisallo Master Fund LP, UTI MF, DSP MF were among the buyers of Sai Life Sciences shares. These entities picked up more than 2.08 crore equity shares or 10 per cent stake in Hyderabad-based Sai Life Sciences, as per the block deal data on the BSE. The transaction, valued at around Rs 1,504.75 crore, was executed at an average price of Rs 722 apiece. Meanwhile, Nippon India MF picked up 49.86 lakh shares or 2.39 per cent holding in Sai Life Sciences. After the stake buy, Nippon India MF's stake in the company rose to 4.88 per cent from 2.48 per cent. Meanwhile, global asset manager TPG through its affiliate TPG Asia VII SF offloaded the equal number of shares in 25 tranches at the same price. Following the stake sale, TPG's holding in Sai Life Sciences declined to 14.73 per cent from 24.73 per cent. Shares of Sai Life Sciences rose 5.03 per cent to close at Rs 765.85 apiece on the BSE. In December last year, Sai Life Sciences raised Rs 3,043 crore through its initial public offering and the shares of the company made a stellar debut on the bourses. Sai Life Sciences provides end-to-end services across the drug discovery, development and manufacturing value chain for small molecule new chemical entities (NCE) to global pharmaceutical innovator companies and biotechnology firms.
Economic Times
20-06-2025
- Business
- Economic Times
TPG offloads Rs 1,505 cr stake in Sai Life via block deals; Norges Bank, MFs step in
Global investor TPG sold its ₹1,505 crore stake in Sai Life Sciences via block deals at ₹722 per share. Key buyers included Norges Bank and top Indian mutual funds. The stock rallied 5% post-deal, reflecting robust investor appetite. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Global investment firm TPG offloaded stake worth Rs 1,505 crore in Sai Life Sciences through block deals on Friday, paving the way for a host of marquee investors to step in, including Norges Bank and leading Indian mutual sold over 2 crore shares in two tranches at Rs 722 per share, a price that reflected a 1% discount to Thursday's closing the key buyers, Norway's central bank, Norges Bank, acquired 11.5 lakh shares worth Rs 83 crore, signaling strong foreign institutional interest in the Indian pharmaceutical the domestic front, several top mutual funds participated in the transaction:-- Nippon India Mutual Fund bought over 40 lakh shares for Rs 290 crore,-- Invesco Mutual Fund acquired 13.5 lakh shares worth Rs 97.5 crore, and-- Aditya Birla Sun Life Mutual Fund picked up 13.85 lakh shares for Rs 100 appetite appeared strong, as shares of Sai Life Sciences rallied 5% to close at Rs 765.85 on the BSE following the block stake reshuffle highlights the growing confidence of both global and domestic institutional investors in Sai Life's long-term growth prospects amid the increasing relevance of India in the global pharma outsourcing held over 5.15 crore equity shares in the company as on March 31, 2025 through TPG Asia VII SF PTE Ltd, which accounts for a 24.73% stake in this smallcap company. The market capitalisation of the company is at Rs 15,230 crore. The stock of Sai Life Sciences was listed on the exchanges on December 18, stock has gained nearly 2% since its listing on December 18, 2024 and its returns on the year-to-date basis remain at 3%. This is an underperformance versus Nifty which has given returns of 6.6% and 5.7%, Life Sciences is a contract research, development, and manufacturing organisation (CRDMO) among listed Indian peers. The company has operations in the UK, the USA and company reported a 57% year-on-year profit in its Q4FY25 net profit at Rs 88 crore versus Rs 56 crore reported in the year ago period. The total revenue from operations in the January-March quarter of FY25 stood at Rs 589 crore, which was growth of 33% versus Rs 443 crore posted by the company in the corresponding quarter of the previous financial to Trendlyne data, shares of Sai Life Sciences are trading above its 50-day and 100-day simple moving averages (SMAs) of Rs 727 and Rs 715, stock has been quite volatile since the last 3 months. Its 1-year beta is at 1.4.
Time of India
20-06-2025
- Business
- Time of India
TPG offloads Rs 1,505 cr stake in Sai Life via block deals; Norges Bank, MFs step in
Global investment firm TPG offloaded stake worth Rs 1,505 crore in Sai Life Sciences through block deals on Friday, paving the way for a host of marquee investors to step in, including Norges Bank and leading Indian mutual funds. TPG sold over 2 crore shares in two tranches at Rs 722 per share, a price that reflected a 1% discount to Thursday's closing price. Among the key buyers, Norway's central bank, Norges Bank, acquired 11.5 lakh shares worth Rs 83 crore, signaling strong foreign institutional interest in the Indian pharmaceutical sector. On the domestic front, several top mutual funds participated in the transaction: -- Nippon India Mutual Fund bought over 40 lakh shares for Rs 290 crore, -- Invesco Mutual Fund acquired 13.5 lakh shares worth Rs 97.5 crore, and -- Aditya Birla Sun Life Mutual Fund picked up 13.85 lakh shares for Rs 100 crore. Investor appetite appeared strong, as shares of Sai Life Sciences rallied 5% to close at Rs 765.85 on the BSE following the block deals. The stake reshuffle highlights the growing confidence of both global and domestic institutional investors in Sai Life's long-term growth prospects amid the increasing relevance of India in the global pharma outsourcing ecosystem. TPG held over 5.15 crore equity shares in the company as on March 31, 2025 through TPG Asia VII SF PTE Ltd, which accounts for a 24.73% stake in this smallcap company. The market capitalisation of the company is at Rs 15,230 crore. The stock of Sai Life Sciences was listed on the exchanges on December 18, 2024. The stock has gained nearly 2% since its listing on December 18, 2024 and its returns on the year-to-date basis remain at 3%. This is an underperformance versus Nifty which has given returns of 6.6% and 5.7%, respectively. Sai Life Sciences is a contract research, development, and manufacturing organisation (CRDMO) among listed Indian peers. The company has operations in the UK, the USA and Japan. The company reported a 57% year-on-year profit in its Q4FY25 net profit at Rs 88 crore versus Rs 56 crore reported in the year ago period. The total revenue from operations in the January-March quarter of FY25 stood at Rs 589 crore, which was growth of 33% versus Rs 443 crore posted by the company in the corresponding quarter of the previous financial year. According to Trendlyne data, shares of Sai Life Sciences are trading above its 50-day and 100-day simple moving averages (SMAs) of Rs 727 and Rs 715, respectively. The stock has been quite volatile since the last 3 months. Its 1-year beta is at 1.4.
Business Standard
20-06-2025
- Business
- Business Standard
Sai Life Sciences rises on completion of second phase expansion at Bidar facility
Sai Life Sciences rose 1.82% to Rs 742.45 after the company announced the successful commencement of commercial operations for the second phase of the production block at its Unit IV facility in Bidar, Karnataka. The new phase, which became operational on 19 June 2025, adds approximately 91 kL of production capacity. This marks the second and final phase of the total planned capacity addition of approximately 195 kL at the facility, as disclosed in the companys prospectus. With this addition, the total installed capacity at Unit IV now stands at approximately 640 kL. The expanded facility is equipped to manufacture Registered Starting Materials (RSM), intermediates, and Active Pharmaceutical Ingredients (APIs) for both clinical and commercial applications. Hyderabad-based Sai Life Sciences is a leading global contract research, development, and manufacturing organization (CRDMO) that partners with innovator pharmaceutical and biotech companies to accelerate the discovery, development, and commercialization of new medicines. The company offers integrated solutions spanning medicinal chemistry, process development, clinical and commercial manufacturing, and advanced technology platforms. The company's net profit surged 105% to Rs 170 crore on a 16% increase in revenue from operations to Rs 1,695 crore in Q4 March 2025 over Q4 March 2024.
Business Upturn
20-06-2025
- Business
- Business Upturn
Sai Life Sciences begins commercial operations of expanded Unit IV facility in Bidar
Sai Life Sciences has recently informed exchanges that the company successfully commenced commercial operations of the second phase of its production block at the Unit IV facility in Bidar, Karnataka, as of June 19, 2025. This phase adds around 91 kL of manufacturing capacity, marking the completion of the company's planned 195 kL expansion project at the site, as outlined in its prospectus. With this addition, the total installed capacity at the Bidar facility now stands at approximately 640 kL. The expanded unit is fully equipped to manufacture Registered Starting Materials (RSMs), intermediates, and Active Pharmaceutical Ingredients (APIs), catering to both clinical development and commercial-scale supply. This strategic milestone strengthens Sai Life Sciences' manufacturing footprint and aligns with its long-term growth plans in the pharmaceutical sector. The company's enhanced infrastructure will support its global clientele with high-quality and scalable production capabilities. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
